文献速递心脑血管急症重症综合管理与镇静镇痛

神经脊柱ICU中左乙拉西坦静脉推注的给药时间、苯二氮䓬使用及安全性评估

Evaluation of Time to Administration, Benzodiazepine Use, and Safety of Intravenous Push Levetiracetam in a Neuro-Spine Intensive Care Unit.
PubMed 文献 · Neurocrit Care · 2021-06-03
一句话结论在神经脊柱ICU活动性癫痫成人中,左乙拉西坦1000mg及以上改为2-5分钟静脉推注可显著缩短给药时间并减少苯二氮䓬 interim 使用,且不良事件无差异。

本研究为回顾性观察性研究,纳入神经脊柱ICU中因活动性癫痫接受至少一剂1000mg及以上左乙拉西坦静脉推注或静脉 piggyback 的成人患者,比较政策变更前后6个月的情况。主要终点为从医嘱核验到给药的时间,静脉推注组显著短于 piggyback 组(28 vs. 80 min,p<0.0001)。次要终点显示静脉推注组在医嘱核验至给药期间接受苯二氮䓬的比例更低(2% vs. 13%,p=0.042)。两组不良事件发生率无差异,提示至多2000mg的左乙拉西坦静脉推注是安全的给药方式。

要点

  • 对于神经脊柱ICU中活动性癫痫成人,左乙拉西坦1000mg及以上静脉推注较15分钟 piggyback 显著缩短给药时间(28 vs. 80 min,p<0.0001)。
  • 静脉推注组在医嘱核验至给药期间接受苯二氮䓬的患者比例显著低于 piggyback 组(2% vs. 13%,p=0.042)。
  • 两组不良事件发生率无差异,支持至多2000mg左乙拉西坦静脉推注的安全性。
  • 本研究为单中心回顾性观察性研究,样本量160例(静脉推注60例,piggyback 100例),结论需前瞻性验证。

适用人群与场景

  • 纳入:成人患者,入住神经脊柱ICU,在政策变更前后6个月内因活动性癫痫接受至少一剂1000mg或更高剂量的左乙拉西坦静脉推注或静脉 piggyback。
  • 排除:原文未提及。

诊断标准与关键阈值

  • 活动性癫痫:原文未提供具体诊断标准或界值。
  • 肾功能不全定义:肌酐清除率低于60 ml/min。
  • 左乙拉西坦剂量阈值:1000mg或更高。

处置流程与药物剂量

  • 第一步:对于神经脊柱ICU中活动性癫痫成人,医嘱左乙拉西坦1000mg或更高剂量。
  • 第二步:采用未稀释静脉推注,给药时间2-5分钟(政策变更后方案),替代15分钟静脉 piggyback。
  • 药物剂量:左乙拉西坦1000mg或更高,最高至2000mg,静脉推注2-5分钟;具体频次和疗程原文未提及。
  • 目标:缩短从医嘱核验到给药的时间,减少 interim 苯二氮䓬使用。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:单中心、回顾性、观察性、机构审查委员会批准的研究;样本量160例患者(静脉推注组60例,piggyback 组100例),来自神经脊柱ICU。
  • 人群基线:多数为男性,年龄57岁,无显著肾功能不全(肌酐清除率<60 ml/min),癫痫病因多为恶性肿瘤或创伤性脑损伤。
  • 主要终点:从医嘱核验到给药时间,静脉推注组显著短于 piggyback 组(28 vs. 80 min,p<0.0001)。
  • 关键次要终点:医嘱核验至给药期间接受苯二氮䓬的患者比例,静脉推注组显著低于 piggyback 组(2% vs. 13%,p=0.042)。
  • 不良事件:两组不良事件发生率无差异。

证据类型、等级与局限

  • 证据类型:回顾性观察性研究。
  • 证据等级或推荐强度:原文未提及。
  • 局限:单中心、回顾性设计、样本量较小(160例),可能存在选择偏倚和混杂;政策变更前后比较,非随机分组。

对床旁实践的改变

  • 对于神经脊柱ICU中活动性癫痫成人,可考虑将左乙拉西坦1000mg及以上剂量改为2-5分钟静脉推注,以缩短给药时间并减少 interim 苯二氮䓬使用。
  • 适用人群:成人神经脊柱ICU患者,活动性癫痫,左乙拉西坦剂量1000mg或更高,无显著肾功能不全(肌酐清除率≥60 ml/min)。
  • 不适用人群:原文未明确排除,但肾功能不全(肌酐清除率<60 ml/min)患者占比少,需谨慎。
  • 常见陷阱:本研究为回顾性单中心研究,结论不能推广至其他ICU人群或儿童;最高剂量2000mg的安全性数据有限。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

PURPOSE: The purpose of this study was to evaluate the time to medication administration, clinical effect, and safety of a recent Pharmacy and Therapeutics Committee-approved change in the administration of levetiracetam from intravenous piggyback (IVPB) over 15 min to undiluted intravenous push (IVP) over 2-5 min at a large academic medical center.

METHODS: The primary outcome was the time from order verification to the administration of IVP levetiracetam versus IVPB levetiracetam. The secondary outcome was any benzodiazepine administered in the time between levetiracetam order verification and administration in both groups. Adult patients admitted to the neuro-spine intensive care unit in the 6 months prior to and after the policy change, and who received at least one dose of 1000 mg or higher of IVP or IVPB levetiracetam for active seizures, were included in this retrospective, observational, institutional review board-approved study. Data were analyzed using descriptive statistics, χ2, and the Mann-Whitney U-test as appropriate.

RESULTS: Of the 2055 hospital-wide levetiracetam doses ordered within the study period, 316 doses were screened for enrollment and 160 were enrolled with 60 and 100 patients assigned to the IVP and IVPB groups, respectively. There were no differences between the groups at baseline. The majority of the population was male, 57 years old, had no significant renal dysfunction (defined as a creatinine clearance of less than 60 ml/min), and had a seizure etiology of malignancy or traumatic brain injury. A significant reduction in the time to administration of levetiracetam was found with IVP compared with IVPB administration (28 vs. 80 min, p < 0.0001). A subsequent reduction in patients who received benzodiazepines in the interim of levetiracetam order verification and administration was also associated with IVP compared with IVPB (2% vs. 13%, p = 0.042). There were no differences found in the rates of adverse effects between groups.

CONCLUSIONS: Administration of levetiracetam doses up to 2000 mg via IVP is a safe method of administration that results in a reduction of time to medication administration and a reduction of benzodiazepine use.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Adams T, Greathouse K. Evaluation of Time to Administration, Benzodiazepine Use, and Safety of Intravenous Push Levetiracetam in a Neuro-Spine Intensive Care Unit. Neurocrit Care. 2021. PMID: 34081297. doi:10.1007/s12028-021-01237-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。